OMCL Stock Recent News
OMCL LATEST HEADLINES
Omnicell, Inc., a small cap medical technology solutions provider, posted its Q1 results Tuesday. Both top and the bottom-line results beat the consensus. However, thanks to some new headlines and reduced forward guidance, OMCL shares sold off 15% in trading yesterday. A buying opportunity? An analysis around Omnicell follows in the paragraphs below.
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
Omnicell, Inc. (NASDAQ:OMCL ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Kathleen Nemeth - SVP, IR Randall Lipps - Founder, Chairman, President and CEO Nchacha Etta - EVP and CFO Nnamdi Njoku - COO Conference Call Participants Jessica Datson - Piper Sandler Gene Mannheimer - Freedom Capital Markets Allen Lutz - Bank of America Bill Sutherland - Benchmark Stan Berenshteyn - Wells Fargo Matt Hewitt - Craig-Hallum Capital David Larsen - BTIG Operator Good morning, my name is Carly and I will be your conference operator today. At this time, I would like to welcome everyone to the Omnicell First Quarter 2025 Financial Results Conference Call.
Omnicell (OMCL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.03 per share a year ago.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces First Quarter 2025 Results.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
OMCL stays on investors' radar due to the strong performance of the SaaS and Expert Services portfolio.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer.